Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.43 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL442507 | 0.79 | NOTUM (0.43) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| Hydrochloric Acid SCHEMBL19555684 | 0.78 | NOTUM (0.42) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL9548280 | 0.74 | NOTUM (0.40) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| Hydrochloric Acid SCHEMBL9548294 | 0.73 | EPHX2 (0.36) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3131551 | 0.71 | — | — | |
| Muscimol SCHEMBL5781030 | 0.71 | NOTUM (0.47) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| Muscimol SCHEMBL8680242 | 0.70 | NOTUM (0.46) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| Muscimol SCHEMBL352714 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL567950 | 0.70 | — | — | |
| Muscimol SCHEMBL7440548 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | NOTUM 1823/4885CYP2E1 269/4885CYP2A6 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.